Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

Comment by KOkidneydiseaseon Nov 15, 2021 6:24pm
91 Views
Post# 34129462

RE:RE:RE:Significantly Undervalued and Strong Buy

RE:RE:RE:Significantly Undervalued and Strong BuyHey Ankle, you're right about the others doing their own DD on their investments but I feel bad for them all the same so I'll just throw some rationale out there for them.

The last 2 financings were done largely to funds managed by managers wayyyyy smarter than myself so I get some comfort in the fact the 1St financing was for $12mm of smart money but I take even greater comfort the 2nd partial over alottment was closed when the share price was below the price of the financing. That tells me these smart fund managers are taking a longer view on their investment as we should all be doing. 

I'm thinking we're currently heading into the soft, slow, tax selling period before Christmas so the price is what it is but also, lets see what happens Jan, Feb 2022 when funds get new RRSP, TFSA money in and have to place that new money. That is when XORTX should be promoting the company resulting in a higher share price!

Patience my friends. I've purchased some more at these lower prices because I could and should!

Thanks Ankle
<< Previous
Bullboard Posts
Next >>